Smith+Nephew launches EVOS PELVIC Plating System
Analysis based on 8 articles · First reported Sep 23, 2026 · Last updated Sep 23, 2026
The launch is an incremental product-line extension for Smith & Nephew rather than a transformative event, so it is unlikely to move the shares materially on its own, though it supports the company's trauma franchise and long-term revenue growth narrative. Investor attention will focus on whether EVOS PELVIC gains adoption in the United States and on the timing of international rollouts, which could modestly lift sentiment toward the medical technology sector.
Smith & Nephew announced the launch of the EVOS PELVIC Plating System, the next evolution of its EVOS plating platform, designed for pelvic and acetabular fracture surgery. The all-in-one system combines pre-contoured plates for the posterior wall, quadrilateral surface and pubic symphysis, locking and non-locking utility plates, a new cannulated screw system built specifically for the pelvis and acetabulum, and specialized instrumentation supporting exposure, fracture reduction and implant placement. According to the company, the system is built on the proven principles of the EVOS platform and aims to make technically demanding pelvic procedures more efficient and reproducible. Nate Folkert, President of Smith+Nephew Orthopaedics, called the launch an important milestone in the expansion of the EVOS Plate portfolio. John Rawlinson, Senior Director of Global Marketing, said the EVOS brand reflects the company mission to drive the Evolution of Osteosynthesis. Reza Firoozabadi, Professor of Orthopedic Surgery at the University of Washington and Harborview Medical Center and a design surgeon for the system, said it was developed to address the full spectrum of pelvic ring and acetabular injuries, from straightforward to the most complex, including elderly patients with compromised bone quality. The EVOS PELVIC System is currently available in the United States, with availability and launch timing in other markets varying. It will be previewed at Smith+Nephew booth 301 during the 2026 Orthopaedic Trauma Association Annual Meeting in Nashville, Tennessee, September 23-26. Smith & Nephew is listed on the Aquis Stock Exchange and the New York Stock Exchange and is a constituent of the FTSE 100 Index, with annual sales of 6.2 billion dollars in 2025 and around 17,000 employees.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard